<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03978559</url>
  </required_header>
  <id_info>
    <org_study_id>MICU-PCP</org_study_id>
    <nct_id>NCT03978559</nct_id>
  </id_info>
  <brief_title>Trimethoprim/Sulfamethoxazole Combined With Caspofungin as First-line Therapy in PCP</brief_title>
  <official_title>A Prospective Randomized Controlled Study to Compare Efficacy of Caspofungin Combined With Trimethoprim-sulfamethoxazole Versus Trimethoprim/Sulfamethoxazole as First-line Therapy in Non-HIV Patients With Severe Pneumocystis Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bin Du</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized clinical trial. During the study, non-HIV patients who are
      admitted to ICU due to Pneumocystic pneumonia (PCP) and have not received anti-PCP therapy or
      have received therapy less than 48hrs will be randomized (1:1) to received caspofungin
      combined with trimethoprim-sulfamethoxazole or trimethoprim-sulfamethoxazole alone.

      The aim of this study is to compare the effectiveness of caspofungin combined with
      trimethoprim-sulfamethoxazole with that of conventional therapy
      (trimethoprim-sulfamethoxazole alone) as first-line therapy in the treatment of severe
      Pneumocystis pneumonia (PCP) in non-HIV patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 14, 2019</start_date>
  <completion_date type="Anticipated">July 8, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 20, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mortality to day 28</measure>
    <time_frame>28 days after randomization</time_frame>
    <description>The percentage of subjects death at study day 28. Those subjects discharged from ICU prior to day 28 were counted as alive at day 28</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICU Free Days to day 28</measure>
    <time_frame>28 days after randomization</time_frame>
    <description>defined as the number of days between randomization and day 28 in which the patient is not in the ICU (for any part of a day)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Ventilator Free Days to day 28</measure>
    <time_frame>28 days after randomization</time_frame>
    <description>Ventilator-free days is defined to be 28 days minus the duration of mechanical ventilation through day 28. Participants who do not survive to day 28 are assigned zero ventilator-free days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU mortality</measure>
    <time_frame>through ICU discharge, an average of 14 days</time_frame>
    <description>The percentage of death subjects at ICU discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospital mortality</measure>
    <time_frame>through hospital discharge, an average of 28 days</time_frame>
    <description>The percentage of death subjects at hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PO2/FiO2 on day 7, 21</measure>
    <time_frame>day 7, 21 after randomization</time_frame>
    <description>the change of PO2/FiO2 between baseline and day7, 21</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum (1,3)-β-D gluca level on day 3, 7, 21</measure>
    <time_frame>day3, 7, 21 after randomization</time_frame>
    <description>the change of (1,3)-β-D glucan level between baseline and day3, 7, 21</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PCP-DNA negative conversion rate in alveolar lavage fluid on day 7 after randomization</measure>
    <time_frame>day 7 after randomization</time_frame>
    <description>the percentage of PCP-DNA negative after 7days treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA</measure>
    <time_frame>day3, 7, 21 after randomization</time_frame>
    <description>respiratory dysfunction assessed by Sequential Organ Failure Assessment (SOFA) score for respiratory system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BALF cytokines level on day3, 7, 21</measure>
    <time_frame>day3, 7, 21 after randomization</time_frame>
    <description>the change of cytokines in bronchoalveolar lavage fluid (BALF) level between baseline and day7, day21</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>till 21 days after randomization</time_frame>
    <description>incidence, duration and severity of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serious adverse events</measure>
    <time_frame>till 21 days after randomization</time_frame>
    <description>incidence, duration and severity of serious adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>Pneumocystis Pneumonia</condition>
  <arm_group>
    <arm_group_label>CAS with TMP/SMZ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TMP/SMZ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>caspofungin</intervention_name>
    <description>caspofungin 70mg ivdrip the first day, then 50mg ivdrip qd for 21days</description>
    <arm_group_label>CAS with TMP/SMZ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TMP/SMZ(trimethoprim/sulfisoxazole)</intervention_name>
    <description>TMP:15mg/kg/d for 21 days +SMZ:75mg/kg/d for 21days</description>
    <arm_group_label>CAS with TMP/SMZ</arm_group_label>
    <arm_group_label>TMP/SMZ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>40mg ivdrip q12h for 5 days , then 40mg ivdrip qd for 5 days , 20mg for 11 days</description>
    <arm_group_label>CAS with TMP/SMZ</arm_group_label>
    <arm_group_label>TMP/SMZ</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years old

          2. Non-HIV immunosuppressed patients admitted to the ICU

          3. confirmed or suspect PCP

        3) Not receiving anti-PCP treatment or anti-PCP treatment &lt; 48 hours

        Exclusion Criteria:

          1. Age less than 18 years old

          2. Known pregnancy

          3. allergy to TMP/SMZ or caspofungin

          4. Decision to withhold life-sustaining treatment

          5. Patients with advanced pulmonary fibrosis

          6. severe liver dysfunction(Child-Pugh C )
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bin Du</last_name>
    <phone>0086-10-69155036</phone>
    <email>dubin98@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>JINMIN PENG</last_name>
    <phone>0086-10-69154040</phone>
    <email>pjm731@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MICU of Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bin Du, Dr</last_name>
      <phone>(8610)69155036</phone>
      <email>dubin98@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 5, 2019</study_first_submitted>
  <study_first_submitted_qc>June 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2019</study_first_posted>
  <last_update_submitted>September 11, 2019</last_update_submitted>
  <last_update_submitted_qc>September 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Bin Du</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia, Pneumocystis</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Caspofungin</mesh_term>
    <mesh_term>Sulfisoxazole</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

